FORM 4

obligations may continue. See

Instruction 1(b)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* COVINO GREGORY F						2. Issuer Name and Ticker or Trading Symbol BIOGEN INC. [BIIB]									k all appl Direct	tionship of Reporting all applicable) Director Officer (give title		g Person(s) to Issuer 10% Owner Other (specify		
(Last) BIOGEN 225 BIN	•	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 05/01/2016) ``	ount	below) ing Office	·		
(Street) CAMBR (City)			02142 (Zip)		_ 4. I	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Inc Line)									´					
		Tab	le I - No	n-Deriv	ative	Sec	uriti	es Ac	quired	, Dis	posed (of, or Be	enefici	ally	Owne	d				
Date			2. Transa Date (Month/E		Ex r) if a	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			and 5) Securit		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									Code	v	Amount	(A) or (D) Prid			Transaction(s) (Instr. 3 and 4)					
Common Stock 05,				05/01	/2016	2016			М		348	A		0	3,119.8231(1)			D		
Common	Common Stock 05/01/				/2016	2016			F		113	D	\$27	274.99 3		3,006.8231		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution I if any (Month/Day	n Date,	4. Transa Code (8)		n of		6. Date Ex Expiration (Month/Da	n Date	•		mount of ecurities		Price of erivative ecurity nstr. 5)		Owne Form Direct or Ind (I) (In	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amour or Number of Shares	er						
Restricted	\$0	05/01/2016			M	M		348	(2)		5/01/2016 Common		348		\$0	0		D		

Explanation of Responses:

Stock Unit

- $1.\ Includes\ 84.8551\ shares\ acquired\ under\ the\ Biogen\ Inc.\ employee\ stock\ purchase\ plan\ on\ 03/31/16.$
- 2. The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 150% of the number of shares at target payout. One-fourth of these RSUs are eligible to vest on each of the first four anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen Idec common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the average 60 calendar-day closing stock price ending on the vesting date divided by the average 60 calendar-day closing stock price on the grant date]).

/s/ Matthew S. Gilman,

Attorney-in-fact for Gregory 05/02/2016

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.